Detection of type IV collagenase activity in malignant ascites

World Journal of Gastroenterology

Volumn 9, Issue 11, 2003, Pages 2592-2595

  Sun, Xiao Min ^a   Dong, Wei Guo ^a   Yu, Bao Ping ^a   Luo, He Sheng ^a   Yu, Jie Ping ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; GELATIN; GELATINASE A; GELATINASE B; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; ASCITES HEPATOMA; ASCITES TUMOR; CELL FREE SYSTEM; CENTRIFUGATION; COLON CANCER; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FEMALE; FREEZING; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; PARACENTESIS; PERITONEUM CANCER; QUALITATIVE ANALYSIS; STATISTICAL ANALYSIS; STOMACH CANCER; TREATMENT PLANNING; TUBERCULOUS PERITONITIS; ZYMOGRAPHY;

EID: 0344036200     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i11.2592     Document Type: Article

References (37)

1. Meyer T, Hart IR. Mechanisms of tumor metastasis. Eur J Cancer 1998; 34: 214-221
2. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42-51
3. Conway JG, Trexler SJ, Wakefield JA, Marron BE, Emerson DL, Bickett DM, Deaton DN, Garrison D, Elder M, McElroy A, Willmott N, Dockerty AJ, McGeehan GM. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 1996; 14: 115-124
4. Heppner KJ, Matrisian LM, Jensen RA, Rodaers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-282
5. Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, Okada A. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: Association with tumor progression and clinical outcome. J Pediatr Surg 1998; 33: 1272-1278
6. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Buchler M, Adler G, Gress TM. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. In J Cancer 2000; 85: 14-20
7. Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez-Ottin C, Murophy G, Knauper V. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000; 275: 14809-14816
8. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal organization required for secretion, latency, and activity. Cancer Res 2000; 60: 4745-4751
9. Stock UA, Wiederschain D, Kilroy SM, Shum-Tim D, Khalil PN, Vacanti JP, Mayer Jr JE, Moses MA. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem 2001; 81: 220-228
10. Lauer-Fields JL, Tuzinski KA, Shimokawa K, Nagase H, Fields GB. Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem 2000; 275: 13282-13290
11. Jiang ZS, Gao Y. Biological feature of matrix metalloproteinase and its action in metastasis of liver cancer. Shijie Huaren Xiaohua Zazhi 2000; 8: 1403-1404
12. Wang ZN, Xu RM. Relationship between collagen IV expression and biological behavior of gastric cancer. World J Gastroenterol 2000; 6: 438-439
13. Ji F, Wang WL, Yang ZL, Li YM, Huang HD, Chen WD. Study on the expression of matrix metalloproteinase-2mrna in human gastric cancer. World J Gastroenterol 1999; 5: 455-457
14. He YD, Zhao YW, Kong LF, Yin PZ. Activity alternating of matrix metalloproteinase-2 in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2000; 8: 952-953
15. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993; 24: 209-218
16. Zhu ZY, Du Z, Wang YJ, Zhang W, Sun BC. Examination of E-cadherin and matrix metalloproteinases and its significance in primary HCC. Shijie Huaren Xiaohua Zazhi 2001; 9: 839-840
17. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-329
18. Young TN, Rodriguze GC, Rinehart AR, Bast RC Jr., Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89-99
19. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-65
20. Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N, Kito T. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997; 84: 133-136
21. Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997; 80: 1457-1463
22. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase -2, -9 and tissue inhibitors of metalloproteinase -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20: 1311-1316
23. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, Nakajima M. Serum matrix metalloproteinase -2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101
24. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876-1883
25. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinase in urine of cancer patient. Cancer Res 1998; 58: 1395-1399
26. Zhang Q, Chen LB, Zang J, Chu XY. Detection of matrix metalloproteinases in urine of breast cancer patients with zymography. Nanjing Daxue Xuebao 2002; 38: 192-195
27. Gao Y, Li XN, Li SY, Zong ZH, Wang XR, Yu BZ. Zymographic analysis of MMPs in human cerebrospinal fluid with brain tumor. Zhongguo Yike Daxue Xuebao 2000; 29: 10-12
28. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC. Phase 1 study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-520
29. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998; 4: 1899-1902
30. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23: 526-531
31. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ. Matrix metalloproteinases. Br J Surg 1997; 84: 160-166
32. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinase and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-2072
33. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328
34. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 1997; 277: 225-228
35. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270
36. Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starlings law of capillary hemodynamics revisited. Ann Oncol 2001; 12: 1353-1257
37. Aslam N, Marino CR. Malignant ascites: New concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2000; 161: 2733-2737